logo
An expensive high: Gabon longs to cash in on sacred hallucinogenic remedy

An expensive high: Gabon longs to cash in on sacred hallucinogenic remedy

Malay Mail10-05-2025
LIBREVILLE, May 10 — Beneath yellow fruit, hidden within the roots of the iboga plant in the forests of Gabon, lies a sacred treasure that the country is keen to make the most of.
For centuries, religious devotees have eaten it—a psychotropic shrub that users say has addiction-fighting powers.
It fascinates foreign visitors, psychiatric patients and rich pharmaceutical companies that want to market it.
Now this central African country, where its use is enshrined in ancestral tradition, is scrambling to avoid missing out on the boom.
Teddy Van Bonda Ndong, 31, an initiate in the Bwiti spiritual tradition, calls it 'sacred wood'. He consumes it in small amounts daily, he said, for his 'mental and physical health'.
'It has a lot of power to help human beings,' added Stephen Windsor-Clive, a 68-year-old retiree.
'It's untapped. A mysterious force lies within this plant.'
He travelled to Gabon from Britain and consumed iboga—in a powder ground from its roots—during a 10-day Bwiti ceremony.
He tried it with a view to adopting it as a treatment for his daughter, who suffers from mental illness.
Economic potential
Given the interest, Gabon is seeking to channel the plant onto the international marketplace.
Exports of iboga products, including its active ingredient ibogaine, are few and strictly regulated in the country.
It grows mostly in the wild, but 'more and more effort is being made to domesticate the plant', said Florence Minko, an official in the forestry ministry.
Potentially toxic in high doses, ibogaine can have effects similar to LSD, mescaline or amphetamines, and cause anxiety and hallucinations.
But users believe it can help drug addicts kick their habit and treat post-traumatic stress and neurological illnesses.
Yoan Mboussou, a local microbiologist and Bwiti initiate, hopes to gain an export licence for the 500-milligram ibogaine capsules he produces at his laboratory near the capital Libreville.
He sells them in Gabon as a food supplement, declaring them to have 'anti-fatigue, antioxidant and anti-addictive' qualities.
Iboga, he believes, 'is a potential lever to develop the economy and the whole country'.
Tradition and IP
Countries such as the United States and France class iboga as a narcotic because of health risks identified in studies, especially heart issues. But it is used in treatment centres in countries including the Netherlands, Mexico and Portugal.
Numerous studies have examined its effects—both helpful and harmful—and scientists have taken out dozens of international patents for ibogaine therapeutic treatments.
'Most of those are based on studies of iboga use by Gabonese people, particularly by Bwiti practitioners,' said Yann Guignon, from the Gabonese conservation group Blessings Of The Forest.
Despite the plant's 'colossal therapeutic benefits', 'Gabon is clearly missing out on the economic potential of iboga,' he added.
'It did not position itself in this market in time by developing productive iboga plantations, a national processing laboratory and a proper industrial policy.'
Overseas laboratories meanwhile have worked out how to make synthetic ibogaine and to extract it from other plants, such as Voacanga africana.
That flowering tree is available in greater quantities in Ghana and Mexico, which 'can produce ibogaine at unbeatable prices', said Guignon.
And 'Gabonese traditional knowledge is not protected by intellectual property regulations.'
Currently only one company in Gabon has a licence to export iboga products—though Minko, from the forestry ministry, said the country hopes this number will rise in the coming years.
She said companies were likely to produce more, spurred by revenue guarantees under the Nagoya Protocol, an international agreement on biological diversity and resource-sharing.
She wants the country to obtain a 'made in Gabon' certificate of origin for iboga.
'This is a huge resource for Gabon. We have drawn up a national strategy for the conservation and sustainable use of the product,' she said.
'Gatherings will soon be organised, bringing together all the groups concerned: NGOs, traditional practitioners and scientists.'
Soothing properties
After harvesting iboga to the sound of traditional harps and consuming it in the initiation ceremony, Stephen Windsor-Clive was convinced by the benefits of iboga.
'I definitely want to bring my daughter here and have her have the experience,' he said.
'This is my last attempt to find something which might be of assistance to her.'
Another visitor, Tafara Kennedy Chinyere, travelled from Zimbabwe to discover Gabon and found, in the initiation, relief from anxiety and his 'inner demons'.
'I feel good in my body, in myself,' he said, sitting under a tree after the ceremony.
'I feel like the iboga helped me to let go of things that you no longer need in your life.' — AFP
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Australia worried by Trump's threat to raise US pharma tariffs to 250%
Australia worried by Trump's threat to raise US pharma tariffs to 250%

Free Malaysia Today

time6 days ago

  • Free Malaysia Today

Australia worried by Trump's threat to raise US pharma tariffs to 250%

US President Donald Trump said the US would first impose a 'small' tariff on foreign-made drugs before hiking it to 150% and eventually to 250%. (AP pic) SYDNEY : Australia is very concerned about US President Donald Trump's latest threat to raise tariffs on pharmaceutical imports by up to 250% over the longer term, its health minister said today. Trump said this week that the US would first impose a 'small' tariff on foreign-made drugs before hiking it to 150% within 18 months and eventually to 250% in an effort to boost domestic production. Mark Butler said the plan would be a blow to producers such as CSL, Australia's largest biotech company. 'And that is why we are working so hard to press the case for the continuation of free trade,' he told reporters. Medicines and pharmaceuticals are among Australia's top exports to the US, with around A$2.1 billion (US$1.4 billion) in shipments last year, according to the Australian Bureau of Statistics. There has been some bilateral tension over drug pricing in Australia. In a January submission to the US government, the Pharmaceutical Research and Manufacturers of America trade group said Australia's Pharmaceutical Benefits Scheme was 'egregious and discriminatory' and 'undervalued American innovation,' putting jobs and exports at risk. Butler said the national programme, which subsidises a wide range of prescription medicines for Australians, would not be changed to appease American companies and escape the threatened tariffs. 'To the extent that this is motivated by big pharma companies seeking to lobby the US administration to water down the protections of our PBS, it's simply not up for negotiation under our government,' he said.

AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030
AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030

Malay Mail

time29-07-2025

  • Malay Mail

AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030

LONDON, July 29 — AstraZeneca Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the US, where it has invested US$50 billion (RM212 billion) to expand amid tariff threats from Washington. The performance is a boost for the UK's largest-listed company by market value as the wider sector braces for US tariffs on pharmaceutical imports and navigates pressure after President Donald Trump's order pushing for drugmakers to cut US prices to what other countries pay. AstraZeneca shares rose as much as 2.2 per cent by 0813 GMT. The drugmaker in April forecast only a limited impact from potential US tariffs, adding it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-US trade deal over the weekend will result in a 15 per cent tariff on pharmaceuticals from the region. The US accounted for more than 40 per cent of AstraZeneca's revenue in 2024. The company had prioritised the market — the world's largest, worth US$635 billion — even before Trump's return to office. AstraZeneca is betting on a wave of expected launches of 20 new medicines and its US expansion to reach US$80 billion in annual revenue by 2030 and offset generic competition. On Tuesday, it maintained its 2025 outlook and increased its interim dividend by 3 per cent. 'Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent,' CEO Pascal Soriot said. Cancer drugs outperform Sales of oncology drugs, constituting nearly half of AstraZeneca's revenue, were up 18 per cent at US$6.31 billion at constant currency rates in the quarter. Jefferies analysts said sales of drugs including Tagrisso, Lynparza, Calquence, Truqap and Imfinzi beat expectations. Total revenue for the three months ended June grew 11 per cent to US$14.46 billion, with double-digit growth in the US despite headwinds from changes in US Medicare price negotiations. Core earnings stood at US$2.17 per share. That compares with analysts' expectations of US$2.16, and US$14.15 billion in sales, according to a company-provided consensus. 'Operationally, this is the type of quarter we want to see,' Barclays analysts said. AstraZeneca is also hoping to move on from scandals in its second-biggest market, China, where it this year faced minor fines related to cancer drugs. It is also fighting patent challenges from an individual against Tagrisso. The company also delayed late-stage Avanzar trial data for a key lung cancer treatment to the first half of 2026. — Reuters

UN chief says hunger must never be used as ‘weapon of war'
UN chief says hunger must never be used as ‘weapon of war'

Free Malaysia Today

time28-07-2025

  • Free Malaysia Today

UN chief says hunger must never be used as ‘weapon of war'

More than 280 million Africans are malnourished, with nearly 3.4 million on the brink of famine. (EPA Images pic) ADDIS ABABA : UN chief Antonio Guterres today said food must not be used as a weapon of war as world leaders gathered for a food summit in Africa, where 280 million people face hunger and starvation. The African Union, for its part, urged donors to provide greater support for the world's poorest continent, which is struggling with poverty, unrest and the effects of climate change. 'Hunger fuels instability and undermines peace. We must never accept hunger as a weapon of war,' Antonio Guterres told the UN Food Systems Summit (UNFSS) in the Ethiopian capital Addis Ababa via video link. 'Climate change is disrupting harvests, supply chains and humanitarian aid,' he said. 'Conflict continues to spread hunger from Gaza to Sudan and beyond,' he warned amid a severely deteriorating crisis in Gaza, whose population of more than two million is facing famine and malnutrition. The World Health Organization has warned malnutrition in the occupied Palestinian territory has reached 'alarming levels' since Israel imposed a total blockade on Gaza on March 2. In late May, it began allowing a small trickle of aid to resume but more than 100 NGOs have warned that 'mass starvation' was spreading in the besieged territory. Millions going hungry The summit takes place against the backdrop of aid cuts by the US and other western nations that are badly affecting much of the developing world. Mahmoud Ali Youssouf, head of the African Union's executive commission, said food insecurity was on the rise across Africa, blaming 'climate shocks, conflicts and economic disruptions'. 'At this crucial moment, how many children and mothers on the continent are sleeping hungry?' he asked. 'Millions, certainly. The urgency of the situation is beyond doubt.' Youssouf said that more than 280 million Africans were malnourished, with 'nearly 3.4 million… on the brink of famine'. Roughly 10 million people had been displaced due to drought, floods and cyclones, he added. Youssouf urged AU member states to devote 10 percent of their gross domestic product to agriculture to help foster 'nutritional resilience'. 'But we cannot do this alone. We call on our partners to honour their commitments to finance and support African solutions,' he said. Sudan is 'the largest humanitarian catastrophe facing our world and also the least remembered', Othman Belbeisi, the regional director of the UN's migration agency, IOM, told reporters last week. Since April 2023, Sudan has been torn apart by a power struggle between army chief Abdel Fattah al-Burhan and Mohamed Hamdan Daglo, commander of the rival paramilitary Rapid Support Forces. The fighting has killed tens of thousands and displaced more than seven million people.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store